Late Breaking Abstracts
We would like to thank all researchers who submitted the late-breaking results of their research for presentation at the ESGO 2025 congress.
The Scientific Programme Committee has carefully evaluated all studies and are happy to announce that following studies will be presented in Best oral sessions:
- Chemotherapy With Or Without Pembrolizumab Followed By Maintenance With Olaparib Or Placebo For First-Line Treatment Of Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: Results From The Randomized Phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 Study; presented by Ignace Vergote (Belgium) in Best oral session: Late breaking ovarian cancer
- SUROVA Study: Global Real-World Treatment Strategies And Mortality Risk Prediction In Advanced Ovarian Cancer; presented by Luis Chiva (Spain) in Best oral session: Late breaking ovarian cancer
- Randomized Phase II/III Trial Of 3 Vs 6 Courses Of Neoadjuvant Carboplatin-Paclitaxel Chemotherapy In Stage IIIC Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma from GOGER trial; presented by Claudio Zamagni (Italy) in Best oral session: Late breaking ovarian cancer
- Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab As First-Line Treatment For Endometrial Cancer: Patient-Reported Outcomes In The DUO-E/GOG-3041/ENGOT-EN10 Intent-To-Treat And Mismatch Repair Deficient Populations; and Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab Plus Olaparib As First-Line Treatment For Endometrial Cancer: Patient-Reported Outcomes In The DUO-E/GOG-3041/ENGOT-EN10 Intent-To-Treat And Mismatch Repair Proficient Populations; presented by Larissa A. Meyer (USA) in Best oral session: Endometrial cancer
- Pembrolizumab Or Placebo Plus Adjuvant Chemotherapy With Or Without Radiotherapy In Patients With Newly Diagnosed, High-Risk Endometrial Cancer: Exploratory Analysis Of Disease-Specific Survival From The Phase 3 ENGOT-En11/GOG-3053/KEYNOTE-B21 Study; presented by Toon Van Gorp (Belgium) in Best oral session: Endometrial cancer
- Patient-Reported Outcomes With Pembrolizumab Plus Chemoradiotherapy For High-Risk, Locally Advanced Cervical Cancer: Interim Analysis 2 Results From The Randomised, Double-Blind, Phase 3 ENGOT-Cx11/GOG-3047/KEYNOTE-A18 Study; presented by Vladyslav Sukhin (Ukraine) in Best oral session: Cervical cancer
Discussants will be invited to comment the results and present them in a wider perspective.
Do not miss these exclusive sessions at ESGO 2025 in Rome!